

1 Prevalence and characteristics of genetic disease in adult kidney 2 stone formers

3
4 Manuel A. Anderegg^{1,2,#}, Eric G. Olinger^{1,2,3,4,#}, Matteo Bargagli^{1,2}, Rob Geraghty³, Lea
5 Taylor⁵, Alexander Nater⁵, Rémy Bruggmann⁵, John A. Sayer^{3,6,7}, Bruno Vogt¹, André
6 Schaller^{8,#}, Daniel G. Fuster^{1,2,#}

7
8 ¹Department of Nephrology and Hypertension, Inselspital, Bern University Hospital,
9 University of Bern, Switzerland

10 ²Swiss National Centre of Competence in Research (NCCR) Kidney.CH

11 ³Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne,
12 UK

13 ⁴Center for Human Genetics, Cliniques Universitaires Saint-Luc, Brussels, Belgium

14 ⁵Interfaculty Bioinformatics Unit, University of Bern and Swiss Institute of Bioinformatics
15 (SIB), Switzerland

16 ⁶Renal Services, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon
17 Tyne, UK

18 ⁷National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle
19 Upon Tyne, NE4 5PL UK.

20 ⁸Department of Human Genetics, Inselspital, Bern University Hospital, University of Bern,
21 Switzerland

22
23 # Contributed equally


1 Correspondence to: Daniel G. Fuster; E-mail: daniel.fuster@insel.ch

2

3 Running head: Genetic disease in adult kidney stone formers

ORIGINAL UNEDITED MANUSCRIPT

1 GRAPHICAL ABSTRACT



2

3 ABSTRACT

4 **Background.** Molecular mechanisms of kidney stone formation remain unknown in most
5 patients. Previous studies showed high a heritability of nephrolithiasis, but data on prevalence
6 and characteristics of genetic disease in unselected adults with nephrolithiasis are lacking.
7 This study was conducted to fill this important knowledge gap.

8 **Methods.** We performed whole exome sequencing in 787 participants of the Bern Kidney
9 Stone Registry, an unselected cohort of adults with ≥ 1 past kidney stone episode (KSF), and
10 114 non-stone-forming individuals (NKSF). An exome-based panel of 34 established
11 nephrolithiasis genes was analyzed and variants assessed according to ACMG criteria.
12 Pathogenic (P) or likely pathogenic (LP) variants were considered diagnostic.

13 **Results.** Mean age of KSF was 47 ± 15 years, and 18 % were first time KSF. A Mendelian
14 kidney stone disease was present in 2.9% (23 of 787) of KSF. The most common genetic
15 diagnoses were cystinuria (*SLC3A1*, *SLC7A9*; $n=13$), Vitamin D-24 hydroxylase deficiency
16 (*CYP24A1*; $n=5$) and primary hyperoxaluria (*AGXT*, *GRHPR*, *HOGA1*; $n=3$). 8.1% (64 of

1 787) of KSF were monoallelic for LP/P variants predisposing to nephrolithiasis, most
2 frequently in *SLC34A1/A3* or *SLC9A3R1* (n=37), *CLDN16* (n=8) and *CYP24A1* (n=8). KSF
3 with Mendelian disease had a lower age at the first stone event (30±14 years vs. 36±14 years,
4 p=0.003), were more likely to have cystine stones (23.4 % vs. 1.4 %) and less likely to have
5 calcium oxalate monohydrates stones (31.9 % vs. 52.5 %) compared to KSF without genetic
6 diagnosis. The phenotype of KSF with variants predisposing to nephrolithiasis was subtle and
7 showed significant overlap with KSF without diagnostic variants. In NKSF, no Mendelian
8 disease was detected, and LP/P variants were significantly less prevalent compared to KSF
9 (1.8 % vs. 8.1%).

10 **Conclusion.** Mendelian disease is uncommon in unselected adult KSF, yet variants
11 predisposing to nephrolithiasis are significantly enriched in adult KSF.

12 **Keywords:** kidney stones, mendelian, monogenic, nephrolithiasis, whole exome sequencing

13

14 **KEY LEARNING POINTS**

15 **What was known:**

- 16 • Kidney stone formation is strongly influenced by genetic factors (positive family
17 history in 30-60%) and >30 Mendelian forms of kidney stone disease were described,
18 explaining 6.8 - 29.4% of stones in selected populations.
- 19 • However, the diagnostic utility of whole exome sequencing in unselected adults with
20 nephrolithiasis has not been established.
- 21 • Current strategies to manage this common and relapsing disease are inadequate.

22 **This study adds:**

- 23 • Mendelian disease in unselected adults with nephrolithiasis is rare and far less
24 common than previously reported.

- 1 • Genetic variants predisposing to kidney stone formation are significantly enriched in
2 individuals with nephrolithiasis, yet the associated phenotypes display a significant
3 overlap with individuals without diagnostic variants.
- 4 • While many Mendelian forms of nephrolithiasis can be detected with thorough
5 phenotypic analysis, genetic testing can ameliorate diagnosis in adult stone formers,
6 where phenotypes are often less pronounced.

7 **Potential impact:**

- 8 • Whole exome sequencing allows accurate assessment of Mendelian disease and
9 identification of predisposing variants in adult individuals with nephrolithiasis.
- 10 • Our study highlights the potential of genetic testing to direct patients to personalized
11 therapies and clinical trials.

ORIGINAL UNEDITED MANUSCRIPT

1 INTRODUCTION

2 Nephrolithiasis is a common global healthcare problem ¹. Kidney stones recur frequently and
3 cause substantial morbidity, reduced quality of life and enormous cost ²⁻⁴. A comprehensive
4 phenotypic examination is paramount for the detection of urinary abnormalities and provides
5 an efficient way for the identification of underlying Mendelian disease. Still, in many adult
6 patients with kidney stones, the molecular pathogenesis of clinical traits associated with
7 kidney stone formation (e.g. hypercalciuria) remains unknown. Consequently,
8 undifferentiated dietary and pharmacological preventive measures are initiated, but many
9 patients continue to form stones ^{5,6}. Hence, current strategies in managing this very common
10 and debilitating disease are clearly inadequate. There is an unmet need for novel diagnostic
11 and therapeutic approaches.

12 Kidney stone formation is strongly influenced by genetic factors: a positive family history is
13 present in 30-60% of individuals with kidney stones ⁷, and both twin ⁸ and genealogy ⁹ studies
14 revealed a high heritability of nephrolithiasis. More than 30 Mendelian (also called
15 monogenic) causes of nephrolithiasis have been described thus far ¹⁰. Recent studies have also
16 highlighted the importance of intermediate effect size / incomplete penetrance variants in
17 increasing the risk for nephrolithiasis ¹¹⁻¹⁴. Identification of patients with Mendelian forms of
18 nephrolithiasis remains a major challenge, and no clear consensus exists on clinical
19 parameters to guide genetic testing. Clinical phenotypes can be diagnostic for many
20 Mendelian diseases – if phenotypic screening is diligently performed – and usually prompt
21 personalized genetic testing. Yet, many cases of genetic forms of nephrolithiasis are missed
22 and incorrectly labelled “idiopathic”.

23 Whole exome sequencing (WES) is widely applied as diagnostic tool for rare diseases and the
24 detection of pathogenic variants in cancer ^{15,16}. In contrast, the diagnostic utility of WES has
25 not been established for most constitutional disorders, such as nephrolithiasis. In small,
26 selected cohorts of early-onset or familial nephrolithiasis, a Mendelian cause was identified in

1 6.8 - 29.4% of cases^{10,17-19}. However, the frequency and phenotypic spectrum of genetic
2 disease in sporadic adult-onset nephrolithiasis, by far the most common type encountered in
3 clinical routine, is unknown. To address these important knowledge gaps, we analyzed a
4 WES-based gene panel in a deeply phenotyped, little selected European cohort of 787 adult
5 kidney stone formers (KSF) and in 114 non-stone forming individuals (NKSF).

9 **MATERIALS AND METHODS**

10 **Study cohort**

11 The study was conducted with participants enrolled in the Bern Kidney Stone Registry
12 (BKSR), an observational cohort of adult kidney stone formers described previously and in
13 the SI²⁰⁻²³. Inclusion criteria for the BKSR are i) written informed consent, ii) age \geq 18 years,
14 and iii) \geq 1 past kidney stone episode.

15 Inclusion criteria for NKSF were i) written informed consent, ii) age \geq 18 years, and iii) no
16 history of past kidney stones and no evidence of asymptomatic nephrolithiasis or
17 nephrocalcinosis on ultrasound at enrolment.

19 **Whole exome sequencing and variant calling**

20 Isolation of genomic DNA, exome capture, high-throughput sequencing and bioinformatic
21 analysis including joint variant calling using Genome analysis Toolkit v3.8 (GATK)
22 according to GATK best practices recommendations^{24,25} and annotation using Ensembl
23 Variant Effect Predictor Release 106 (VEP)²⁶ was performed using established methods,
24 described in more detail in Supplemental Methods. After filtering for predicted consequences
25 and genome aggregation database (gnomAD) minor allele frequency (<1% in all populations)
26²⁷, variants in 34 genes^{10,17-19,28} previously implicated in Mendelian kidney stone disease were
27 examined (Fig. 1, lower panel). Further variant stratification was performed according to the

1 recommendations of the American College of Medical Genetics and Genomics (ACMG)²⁹
2 after manual review of phenotype data. Only variants classified as likely pathogenic (LP) or
3 pathogenic (P) applying the ACMG criteria were defined as diagnostic variants leading to a
4 genetic diagnosis. Separation into Mendelian or LP/P variants predisposing to nephrolithiasis
5 (LP/P variants) was conducted depending on evidence available from this study and/or from
6 published case/control studies, described in more detail in the SI.^{11,12,30,31} (Fig. 1 and
7 Supplemental Methods).

8

9 **Statistical Analysis**

10 Continuous variables were reported as medians with 25th-75th percentiles or means with
11 standard deviations and categorical variables were reported as counts with percentages, as
12 appropriate. Different statistical methods were employed to analyze differences between
13 independent groups, depending on the nature of the variables involved. Mann-Whitney U test
14 was used for non-normally distributed continuous variables, while Student's t-test was applied
15 for normally distributed variables. For categorical variables, the Fisher's Exact Test was
16 implemented. Findings from these analyses were summarized and presented as descriptive
17 tables. Statistical tests were two-sided and a p -value < 0.05 was considered statistically
18 significant. Statistical analyses were performed using Stata, version 16 (Statacorp, TX, USA).
19 Pie-charts and dot plots were generated with GraphPad Prism, version 8.4.3 (GraphPad
20 Software, San Diego, CA, USA).

21

1 RESULTS

2 Study cohort

3 We performed WES in 901 individuals, including 787 KSF and 114 NKSF (Fig. 1). Clinical
4 characteristics of the study cohort, separated in KSF and NKSF, are shown in Table 1. Mean
5 age \pm standard deviation (SD) was 46.6 \pm 14.5 years in KSF and 42.4 \pm 14.9 years in NKSF,
6 respectively. The majority of KSF were male (71.8 %, n=565), whereas the percentage of men
7 was lower in NKSF (54 %, n=61). Consistent with previous reports, KSF were significantly
8 more likely to report a positive family history of kidney stones compared to NKSF (43.6 %
9 vs. 6.8 %, Table 1)^{32,33}, and lumbar spine bone mineral density (BMD) was lower in KSF
10 compared to NKSF (Table 1)^{34,35}.

11

12 Genetic analysis

13 Among 787 unrelated, unselected adult KSF, we discovered in 23 patients (2.9 %) a
14 Mendelian form of nephrolithiasis, i.e., pathogenic (P) or likely pathogenic (LP) variants in
15 genes associated with Mendelian forms of nephrolithiasis respecting the relevant mode of
16 inheritance (autosomal dominant and/or autosomal recessive and X-linked recessive) (Table
17 2, Fig. 1, Fig. 2). Mendelian disease was detected in nine of 34 analyzed genes (n= number of
18 patients): *AGXT* (n=1), *ATP6V1B1* (n=1), *CYP24A1* (n=5), *GRHPR* (n=1), *HOGA1* (n=1),
19 *SLC3A1* (n=9), *SLC4A1* (n=1), *SLC7A9* (n=4), *SLC12A1* (n=1).

20 A total of 66 individuals (8.4%), 64 (8.1%) of which were KSF, presented with LP/P variants
21 not fulfilling our stringent criteria for Mendelian disease, but predisposing for nephrolithiasis
22 (Suppl. Table 1). LP/P variants were detected in nine of 34 genes (n=number of patients):
23 *ADCY10* (n=1), *CASR* (n=4), *CLDN16* (n=8), *CYP24A1* (n=8), *SLC4A1* (n=1), *SLC7A9* (n=3),
24 *SLC34A1* (n=15), *SLC34A3* (n=17) and *SLC9A3R1* (n=8). Of these variants, 18 % (12 of 66)
25 were novel, previously unreported in ClinVar or HGMD (Suppl. Table 2).

1 Prior to WES, a Mendelian form of nephrolithiasis was known or suspected in 18 of 23
2 individuals (78 %) with a post WES Mendelian diagnosis, despite each case being reviewed
3 by a kidney stone expert. Therefore, in five of 23 individuals (22 %) with Mendelian disease
4 (that is 5/787, 0.6 % of total KSFs) genetic analysis established a new or corrected a
5 suspected *a priori* diagnosis. The diagnostic yield was similar between first-time and
6 recurrent stone formers (Supplementary Table 3), and between men and women (Table 3,
7 Suppl. Table 4).

8

9 **Genotype-phenotype correlation**

10 Mean age of first kidney stone event (23.5±12.3 years vs. 35.9±13.8 years, $p<0.001$) and
11 mean age of presentation for metabolic-work up (39±15.8 years vs. 47.2±14.3 years, $p=0.009$)
12 were lower in KSF with Mendelian diagnosis compared to KSF without, with intermediate
13 results for patients with LP/P variants predisposing for nephrolithiasis (Table 3, Suppl. Fig.
14 3). Furthermore, cystine stones were significantly more common (64.7 % vs. 1.4 %) and
15 calcium oxalate monohydrates stones less common (23.5 % vs. 52.5 %) in KSF with
16 Mendelian diagnosis compared to KSF with LP/P variants or without genetic diagnosis, in
17 line with higher urinary cystine and urine pH in KSF with Mendelian diagnosis (Table 3,
18 Suppl. Fig. 2). The prevalence of a positive family history of kidney stone disease was similar
19 in all three groups (43.1 % vs. 49.2% vs. 46.0 %). Additionally, KSF with Mendelian disease
20 had more past kidney stone events [5 (2,5) vs. 3 (2,4), $p=0.052$] than KSF with LP/P variants.
21 In contrast, KSF with LP/P variants had significantly lower plasma phosphate (Table 3).
22 Lumbar spine BMD was higher in KSF with Mendelian disease compared to KSF without
23 genetic disease or LP/P variants predisposing for nephrolithiasis (Table 3, Suppl. Fig. 6).

24

1

2 **Mendelian disease**

3 The most common Mendelian diagnosis was cystinuria (n=13) due to biallelic diagnostic
4 variants in *SLC3A1* (type A cystinuria, n=9) or *SLC7A9* (type B cystinuria, n=4). Urine
5 cystine excretion, where available, was increased in all KSF with genetic diagnosis of
6 cystinuria. One patient had biallelic diagnostic variants in *SLC3A1* and a monoallelic LP/P
7 variant in *SLC7A9*. KSF with biallelic diagnostic *SLC3A1* or *SLC7A9* variants all had cystine
8 stones.

9 Five patients had biallelic diagnostic variants in *CYP24A1*, which encodes the Vitamin-D
10 inactivating enzyme Vitamin D-24 hydroxylase. Interestingly, all KSF with biallelic variants
11 in *CYP24A1* (but no KSF with a monoallelic *CYP24A1* variant) displayed cystic kidney
12 disease, as reported previously^{31,36}. Common misdiagnoses for patients with biallelic variants
13 in *CYP24A1* (n=3) were polycystic kidney disease or medullary sponge kidney. Two patients
14 with biallelic *CYP24A1* variants underwent parathyroidectomy for suspected primary
15 hyperparathyroidism (PHPT), without phenotype alleviation postoperatively.

16 We furthermore identified three patients with primary hyperoxaluria (PH) in our cohort. The
17 diagnosis was already established in the two patients with primary hyperoxaluria type 1 (PH1)
18 and primary hyperoxaluria type 2 (PH2), respectively. The diagnosis was previously unknown
19 in the patient with primary hyperoxaluria type 3 (PH3) due to a homozygous pathogenic
20 *HOGA1* variant. This patient had his first kidney stone episode at age 36. Metabolic work-up
21 at age of 67 showed CKD stage 2 and a urine oxalate in the upper normal range on free-
22 choice diet, but a strong increase after an instructed one-week diet low in calcium and sodium.

23 No Mendelian form of nephrolithiasis was detected in the 114 NKSF included in this study
24 (Fig. 1, Fig. 2, Suppl. Table 5).

25

1

2 **LP/P variants predisposing to nephrolithiasis**

3 The most common identified genetic predisposition to nephrolithiasis was renal phosphate
4 wasting due to monoallelic variants in the genes encoding the renal sodium/phosphate co-
5 transporters NaPi-2a and NaPi-2c, *SLC34A1* (n=15), *SLC34A3* (n=18) or in the gene
6 *SLC9A3R1*, encoding the regulatory interaction protein for NaPi-2a/2c, NHERF, (n=7). LP/P
7 variants in *SLC34A1*, *SLC34A3*, but not in *SLC9A3R1*, were enriched in KSF compared with
8 controls (NKSF and gnomAD, Supplementary Table 5). KSF with LP/P variants in
9 *SLC34A1/A3* or *SLC9A3R1* had similar plasma phosphate and TmP/GFR compared to KSF
10 without genetic diagnosis, but urine calcium in individuals with LP/P variants in *SLC34A3*
11 was higher compared to KSF without genetic diagnosis (Suppl. Fig. 4).

12 We also identified eight patients carrying the same previously described monoallelic LP/P
13 variant (c.458A>G, p.Asn153Ser) in *CLDN16*, encoding the tight junction protein claudin-16.
14 Biallelic pathogenic variants in *CLDN16* cause familial hypomagnesemia with hypercalciuria
15 and nephrocalcinosis (FHHNC)³⁷, and an increased prevalence of nephrolithiasis has been
16 observed in monoallelic carriers of pathogenic *CLDN16* variants^{30,38}. Individuals with the
17 monoallelic *CLDN16* variant presented with hypercalciuria and calcium oxalate stones but
18 normal renal function and plasma magnesium. The identified *CLDN16* variant was more
19 prevalent in KSF vs. NKSF and vs. all LP/P-variants in *CLDN16* in gnomAD-NFE,
20 respectively (Suppl. Table 5).

21 Additionally, eight patients carried monoallelic LP/P variants in *CYP24A1*, and the respective
22 variants were five to eight times more prevalent in KSF vs. NKSF and vs. gnomAD-NFE,
23 respectively (Suppl. Table 5). Overall (i.e., considering the prevalence of all variants),
24 *CYP24A1* variants were not enriched in our cohort compared to gnomAD-NFE
25 (Supplementary Table 5). KSF with mono- and biallelic *CYP24A1* variants both displayed
26 hypercalciuria, but hypercalcemia and/or suppressed parathyroid hormone (PTH) or

1 nephrocalcinosis were only present in KSF with biallelic variants. Urine calcium was higher
2 in KSF with biallelic variants, but KSF with monoallelic variants had a higher number of past
3 stone events (Supplemental Fig. 5). BMD and the prevalence of osteoporosis / osteopenia
4 were similar in patients with genetic variants predisposing to urinary phosphate or calcium
5 wasting compared to KSF without genetic diagnosis (Suppl. Fig. 6 and Suppl. Table 7).

6 We furthermore identified six patients with monoallelic LP/P variants in *SLC7A9*. Risk
7 variants were either previously described to cause autosomal-dominant cystinuria (c.544G>A
8 p.(Ala182Thr))^{39,40 41,42}, or enriched in KSF vs NKSF and gnomAD (c.313G>A
9 p.(Gly105Arg)). In contrast to biallelic variants, the six KSF with monoallelic *SLC7A9*
10 variants presented with calcium-containing kidney stones without cystine content, similar to
11 previously reported cases⁴³⁻⁴⁵. KSF with monoallelic *SLC7A9* variants had elevated urine
12 cystine, albeit lower levels compared to KSF with biallelic variants in *SLC3A1/SLC7A9*. No
13 significant differences in stone number or age at first stone event were detected between the
14 two groups of patients (Suppl. Fig. 5). In seven individuals with cystine-containing kidney
15 stones and two individuals with increased urine cystine, no diagnostic variants in *SLC3A1* or
16 *SLC7A9* could be identified (Suppl. Table 6).

17 Four KSF had LP/P variants in the gene encoding the calcium-sensing receptor, *CASR*, which
18 is associated with familial hypocalciuric hypercalcaemia type 1 (FHH1), or autosomal-
19 dominant hypocalcemia. The frequency of *CASR* LP/P variants in KSF was significantly
20 higher than LP/P variants in all gnomAD-NFE participants (Supplementary Table 5). The
21 phenotype of these patients was variable: two patients presented with hypercalciuria but
22 normal plasma calcium, phosphate and PTH. One patient had hypercalcemia with a low-
23 normal PTH and low urine calcium. Another patient presented with elevated PTH,
24 hypercalcemia, pronounced hypophosphatemia, hypercalciuria and calcium oxalate dihydrate
25 stones, compatible with the diagnosis of PHPT. Parathyroidectomy led to a complete
26 normalization of the phenotype.

1 In the 114 NKSF included in this study, exome sequencing revealed a LP/P variant in two
2 individuals, corresponding to a prevalence of variants predisposing to nephrolithiasis of 1.8 %
3 (compared with 8.13% for KSF) (Fig. 1, Fig. 2, Suppl. Table 5).

6 **DISCUSSION**

7 In this exome-based targeted panel study in a large, unselected European cohort of 787 adult
8 KSF, we detected a Mendelian kidney stone disease in 23 patients (2.9 %) using stringent
9 diagnostic criteria. This diagnostic yield is significantly lower compared to previous studies
10 conducted in selected groups of KSF^{10,17,46}. Yet the fraction of additional individuals (8.13%)
11 with LP/P variants predisposing to nephrolithiasis is substantial, especially when considering
12 the broad inclusion criteria, the high prevalence of the disease and the potential rate of false-
13 negatives due to stringent molecular genetic diagnosis criteria and technical limitations of
14 exome sequencing, such as inability to detect deep intronic or difficulty in reliably calling
15 copy-number variants. In fact, if Mendelian disease and variants predisposing to
16 nephrolithiasis are combined, the overall diagnostic yield is 11 % (87 of 787 individuals),
17 comparable to neurometabolic disorders or cancer, where exome sequencing is routinely used
18^{16,47,48}. Interestingly, the diagnostic yield was not different between first time and recurrent
19 stone formers and did not differ when stratified by sex. In NKSF, no Mendelian kidney stone
20 disease was detected, and LP/P variants in nephrolithiasis genes were significantly less
21 prevalent compared to KSF (1.8 % vs. 8.1 %).

22 Cystinuria due to biallelic diagnostic variants in *SLC3A1* or *SLC7A9* was the most common
23 Mendelian disease in our cohort (57 %; n=13 of 23 individuals with Mendelian disease), and
24 an additional six individuals carried monoallelic LP/P variants in *SLC7A9*. We confirmed a
25 high prevalence of CKD in KSF with cystinuria⁴⁹. Yet, this applied only to KSF with biallelic
26 diagnostic variants. We were unable to provide a genetic diagnosis in nine KSF with a

1 cystinuria phenotype, including seven individuals with cystine-containing kidney stones and
2 two individuals with elevated urinary cystine excretion. While this could at least partially be
3 due to technical limitations, such as the inability to detect deep-intronic variants or missed
4 CNVs³⁹, it may also indicate that the genetic architecture of cystinuria is not yet completely
5 deciphered. Of note, the prevalence of phenotypic cystinuria (including patients with elevated
6 urinary cysteine but no cysteine stones) in the BKSr (22/787 KSF; 2.8 %) was only
7 marginally higher than described for adult stone formers (1-2%), but significantly lower than
8 in pediatric cohorts (6-10%)^{50,51}.

9 Of the LP/P variants detected predisposing to nephrolithiasis, by far the most common (63 %;
10 n=40 of 64) were variants in *SLC34A1/3* or *SLC9A3R1*, highlighting the pathophysiological
11 importance of renal phosphate loss in increasing risk for kidney stone formation^{12,52}.

12 However, the phenotype of KSF with LP/P variants in these genes on a free choice diet was
13 very subtle and mostly indistinguishable from KSF without predisposing variants. Future
14 studies need to determine if the phenotype of KSF with LP/P variants in these genes can be
15 unmasked by dietary interventions (e.g., by a low phosphate diet) for diagnostic purposes and
16 mitigated for prevention of future stone events (e.g., by phosphate supplementation).

17 We only detected one KSF with a monoallelic LP/P variant in *ADCY10*, indicating that
18 variants in *ADCY10* are not contributing significantly to the overall nephrolithiasis risk, at
19 least in individuals of European descent^{43,53}. Further, we identified four patients with *CASR*

20 LP/P variants in our cohort with very variable phenotypes. Atypical characteristics such as
21 chondrocalcinosis or kidney stones have been described in patients with *FHH1* but complicate
22 the separation from primary hyperparathyroidism (PHPT)⁵⁴⁻⁵⁶. Yet, separation is of critical

23 importance: parathyroidectomy is the first-line treatment in PHPT but surgery is ineffective in
24 *FHH1*. Additional complexity arises from the fact that PHPT and *FHH1* can co-exist, as
25 observed in patient# 6023^{57,58}. Interestingly, the diagnostic rate in uric acid stone formers was

26 very low, with no Mendelian disease and only one monoallelic LP/P variant (in *ADCY10*)

1 found in 38 uric acid stone formers, suggesting no significant contribution of Mendelian
2 disease in uric acid stone disease.

3 Genetic diagnoses in KSF can have important prognostic implications and therapeutic
4 consequences. However, while the pathophysiology is well delineated, the effectiveness of
5 therapeutic interventions has not been studied systematically in most forms of Mendelian
6 nephrolithiasis. The widespread use of genetic testing will facilitate the inclusion of KSF with
7 Mendelian disease and LP/P variants predisposing to nephrolithiasis in prospective registries
8 and clinical trials to study disease evolution and evaluate tailored therapeutic interventions.
9 Currently, KSF are only subjected to genetic testing if a specific disease is strongly suspected.

10 While clinical signs suggesting an inherited disorder have been proposed ⁵⁹, Mendelian
11 disease was missed or misclassified in five of 23 (22%) KSF in our cohort, despite individual
12 review of each case by a kidney stone expert. The situation is even far more difficult in KSF
13 with LP/P variants predisposing to nephrolithiasis: the associated phenotypes were discrete
14 and variable with a large phenotype overlap with KSF without LP/P variants. Yet, the low
15 prevalence of LP/P variants detected in NKSF suggests a rather high penetrance of LP/P
16 variants predisposing to nephrolithiasis in adults, with the limitation of a small NKSF sample
17 size. Together, these results preclude the definition of clear phenotypic criteria to reliably
18 prioritize genetic testing in adult KSF, with the notable exception of Mendelian forms of
19 nephrolithiasis with clear and unequivocal phenotypes.. In addition, LP/P variants present
20 with their own challenges in clinics and considerations for clinical reporting of LP/P variants
21 and risk alleles have recently been suggested ¹⁴.

22 Strengths of our study include very minor patient pre-selection with broad inclusion criteria,
23 the large sample size, availability of ethnically matched non-stone forming controls and the
24 detailed phenotype. Our study also has limitations, such as the inability to detect deep intronic
25 and copy-number variants, lack of family recruitment for segregation analyses, monocentric
26 recruitment, overrepresentation of men and a limited ethnic diversity.

1 In conclusion, our study shows that Mendelian disease is far less common in adult KSF than
2 previously suggested, but simultaneously reveals a high prevalence of LP/P variants
3 predisposing to nephrolithiasis in adult KSF. Our study also highlights the potential of genetic
4 testing in unselected adult KSF for accurate assessment of Mendelian disease and
5 identification of variants predisposing to nephrolithiasis to direct patients to tailored therapies
6 and clinical trials.

7

8

9 **CONFLICT OF INTEREST STATEMENT**

10 The authors declare no competing interests.

11 **AUTHORS' CONTRIBUTIONS**

12 DGF, AS and JAS conceptualized the study. DGF and MAA acquired financial support.
13 MAA, EGO and DGF designed data analysis plans. MAA, EGO and MB performed data
14 analysis. MAA, EGO, MB, AS and DGF performed data analysis and data interpretation.
15 MAA wrote the first draft of the manuscript. All authors contributed to discussion and editing
16 of text and approved the final version of the manuscript.

17 **FUNDING**

18 MAA was supported by a grant for protected research time by the InselGruppe. EGO was
19 supported by Postdoc Mobility Stipendien of the Swiss National Science Foundation (grants #
20 P2ZHP3_195181 and P500PB_206851), and Kidney Research UK ((grants #
21 Paed_RP_001_20180925). DGF was supported by the Swiss National Science Foundation
22 (grants # 31003A_172974 and 33IC30_166785/1) and the Swiss National Centre of
23 Competence in Research Kidney.CH. JAS is supported by the Northern Counties Kidney
24 Research Fund (22/01), Kidney Research UK (Paed_RP_001_20180925), LifeArc, and the
25 Medical Research Council (MR/Y007808/1).

1 **DATA AVAILABILITY STATEMENT**

2 The data supporting the findings of this study are available from the corresponding author
3 upon request. Stratified genetic data will be accessible upon publication at European Genome-
4 Phenome Archive (EGA) (<https://ega-archive.org/>).

5 **ACKNOWLEDGEMENTS**

6 Part of this work was presented in an abstract form at the American Society of Nephrology
7 Kidney Week, November 3-6, 2022, Orlando, FL. We wish to thank all the patients and staff
8 from all units participating in the study. We also wish to thank Hans Anderegg for technical
9 expertise in database development.

ORIGINAL UNEDITED MANUSCRIPT

1 REFERENCES

- 2 1. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United
3 States from 2007 to 2016. *Urolithiasis*. 2021;49(1):27-39.
- 4 2. Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic
5 calcium kidney stones: analysis of data from the literature. *J Nephrol*. 2017;30(2):227-
6 233.
- 7 3. New F, Somani BK. A Complete World Literature Review of Quality of Life (QOL)
8 in Patients with Kidney Stone Disease (KSD). *Curr Urol Rep*. 2016;17(12):88.
- 9 4. Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an
10 employed population: opportunity for disease management? *Kidney Int*.
11 2005;68(4):1808-1814.
- 12 5. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones:
13 AUA guideline. *The Journal of urology*. 2014;192(2):316-324.
- 14 6. Dhayat NA, Bonny O, Roth B, et al. Hydrochlorothiazide and Prevention of Kidney-
15 Stone Recurrence. *N Engl J Med*. 2023;388(9):781-791.
- 16 7. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney
17 stones. *J Am Soc Nephrol*. 1997;8(10):1568-1573.
- 18 8. Goldfarb DS, Fischer ME, Keich Y, Goldberg J. A twin study of genetic and dietary
19 influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry.
20 *Kidney Int*. 2005;67(3):1053-1061.
- 21 9. Edvardsson VO, Palsson R, Indridason OS, Thorvaldsson S, Stefansson K. Familiality
22 of kidney stone disease in Iceland. *Scand J Urol Nephrol*. 2009;43(5):420-424.
- 23 10. Halbritter J, Baum M, Hynes AM, et al. Fourteen monogenic genes account for 15%
24 of nephrolithiasis/nephrocalcinosis. *J Am Soc Nephrol*. 2015;26(3):543-551.
- 25 11. Sadeghi-Alavijeh O, Chan MMY, Moochhala SH, et al. Rare variants in the sodium-
26 dependent phosphate transporter gene SLC34A3 explain missing heritability of
27 urinary stone disease. *Kidney Int*. 2023.
- 28 12. Nwachukwu C, Singh G, Moore B, Strande NT, Bucaloiu ID, Chang AR. Risk of
29 Nephrolithiasis in Adults Heterozygous for SLC34A3 Ser192Leu in an Unselected
30 Health System Cohort. *J Am Soc Nephrol*. 2023.
- 31 13. Halbritter J. Urinary stone disease: closing the heritability gap by challenging
32 conventional Mendelian inheritance. *Kidney International*. 2023;104(5):882-885.
- 33 14. Lebo M, Steeves M, Benson K, et al. O31: Risk allele evidence curation,
34 classification, and reporting: Recommendations from the ClinGen Low
35 Penetrance/Risk Allele Working Group*. *Genetics in Medicine Open*. 2023;1(1).
- 36 15. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic Utility of Exome
37 Sequencing for Kidney Disease. *N Engl J Med*. 2019;380(2):142-151.
- 38 16. Tarailo-Graovac M, Shyr C, Ross CJ, et al. Exome Sequencing and the Management
39 of Neurometabolic Disorders. *N Engl J Med*. 2016;374(23):2246-2255.
- 40 17. Daga A, Majmundar AJ, Braun DA, et al. Whole exome sequencing frequently detects
41 a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. *Kidney Int*.
42 2018;93(1):204-213.
- 43 18. Braun DA, Lawson JA, Gee HY, et al. Prevalence of Monogenic Causes in Pediatric
44 Patients with Nephrolithiasis or Nephrocalcinosis. *Clin J Am Soc Nephrol*.
45 2016;11(4):664-672.
- 46 19. Amar A, Majmundar AJ, Ullah I, et al. Gene panel sequencing identifies a likely
47 monogenic cause in 7% of 235 Pakistani families with nephrolithiasis. *Hum Genet*.
48 2019;138(3):211-219.
- 49 20. Dhayat NA, Schaller A, Albano G, et al. The Vacuolar H⁺-ATPase B1 Subunit
50 Polymorphism p.E161K Associates with Impaired Urinary Acidification in Recurrent
51 Stone Formers. *J Am Soc Nephrol*. 2016;27(5):1544-1554.

- 1 21. Dhayat NA, Luthi D, Schneider L, Mattmann C, Vogt B, Fuster DG. Distinct
2 phenotype of kidney stone formers with renal phosphate leak. *Nephrol Dial*
3 *Transplant*. 2019;34(1):129-137.
- 4 22. Dhayat NA, Schneider L, Popp AW, et al. Predictors of Bone Mineral Density in
5 Kidney Stone Formers. *Kidney Int Rep*. 2022;7(3):558-567.
- 6 23. Fuster DG, Morard GA, Schneider L, et al. Association of urinary sex steroid
7 hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers.
8 *Nephrol Dial Transplant*. 2022;37(2):335-348.
- 9 24. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and
10 genotyping using next-generation DNA sequencing data. *Nat Genet*. 2011;43(5):491-
11 498.
- 12 25. Poplin R, Ruano-Rubio V, DePristo MA, et al. Scaling accurate genetic variant
13 discovery to tens of thousands of samples. *bioRxiv*. 2018:201178.
- 14 26. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. *Genome*
15 *Biol*. 2016;17(1):122.
- 16 27. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum
17 quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443.
- 18 28. Policastro LJ, Saggi SJ, Goldfarb DS, Weiss JP. Personalized Intervention in
19 Monogenic Stone Formers. *J Urol*. 2018;199(3):623-632.
- 20 29. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of
21 sequence variants: a joint consensus recommendation of the American College of
22 Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet*
23 *Med*. 2015;17(5):405-424.
- 24 30. Weber S, Schneider L, Peters M, et al. Novel paracellin-1 mutations in 25 families
25 with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc*
26 *Nephrol*. 2001;12(9):1872-1881.
- 27 31. Tebben PJ, Milliner DS, Horst RL, et al. Hypercalcemia, hypercalciuria, and elevated
28 calcitriol concentrations with autosomal dominant transmission due to CYP24A1
29 mutations: effects of ketoconazole therapy. *J Clin Endocrinol Metab*.
30 2012;97(3):E423-427.
- 31 32. Resnick M, Pridgen DB, Goodman HO. Genetic predisposition to formation of
32 calcium oxalate renal calculi. *N Engl J Med*. 1968;278(24):1313-1318.
- 33 33. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary
34 calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*.
35 1993;328(12):833-838.
- 36 34. Sakhae K, Maalouf NM, Kumar R, Pasch A, Moe OW. Nephrolithiasis-associated
37 bone disease: pathogenesis and treatment options. *Kidney Int*. 2011;79(4):393-403.
- 38 35. Melton LJ, 3rd, Crowson CS, Khosla S, Wilson DM, O'Fallon WM. Fracture risk
39 among patients with urolithiasis: a population-based cohort study. *Kidney Int*.
40 1998;53(2):459-464.
- 41 36. Hanna C, Potretzke TA, Cogal AG, et al. High Prevalence of Kidney Cysts in Patients
42 With CYP24A1 Deficiency. *Kidney Int Rep*. 2021;6(7):1895-1903.
- 43 37. Simon DB, Lu Y, Choate KA, et al. Paracellin-1, a renal tight junction protein
44 required for paracellular Mg²⁺ resorption. *Science*. 1999;285(5424):103-106.
- 45 38. Praga M, Vara J, Gonzalez-Parra E, et al. Familial hypomagnesemia with
46 hypercalciuria and nephrocalcinosis. *Kidney Int*. 1995;47(5):1419-1425.
- 47 39. Font-Llitjos M, Jimenez-Vidal M, Bisceglia L, et al. New insights into cystinuria: 40
48 new mutations, genotype-phenotype correlation, and digenic inheritance causing
49 partial phenotype. *J Med Genet*. 2005;42(1):58-68.
- 50 40. Gaildrat P, Lebbah S, Tebani A, et al. Clinical and molecular characterization of
51 cystinuria in a French cohort: relevance of assessing large-scale rearrangements and
52 splicing variants. *Mol Genet Genomic Med*. 2017;5(4):373-389.

- 1 41. Font MA, Feliubadalo L, Estivill X, et al. Functional analysis of mutations in
2 SLC7A9, and genotype-phenotype correlation in non-Type I cystinuria. *Hum Mol*
3 *Genet.* 2001;10(4):305-316.
- 4 42. Reig N, Chillaron J, Bartoccioni P, et al. The light subunit of system b(o,+) is fully
5 functional in the absence of the heavy subunit. *EMBO J.* 2002;21(18):4906-4914.
- 6 43. Halbritter J, Baum M, Hynes AM, et al. Fourteen Monogenic Genes Account for 15%
7 of Nephrolithiasis/Nephrocalcinosis. *J Am Soc Nephrol.* 2014.
- 8 44. Elkoushy MA, Andonian S. Characterization of patients with heterozygous cystinuria.
9 *Urology.* 2012;80(4):795-799.
- 10 45. Cupisti A, Farnesi I, Armillotta N, Francesca F. Staghorn cystine stone in a 72-year-
11 old recurrent calcium stone former. *Clin Nephrol.* 2012;78(1):76-80.
- 12 46. Schonauer R, Scherer L, Nemitz-Kliemchen M, et al. Systematic assessment of
13 monogenic etiology in adult-onset kidney stone formers undergoing urological
14 intervention-evidence for genetic pretest probability. *Am J Med Genet C Semin Med*
15 *Genet.* 2022;190(3):279-288.
- 16 47. Huang KL, Mashl RJ, Wu Y, et al. Pathogenic Germline Variants in 10,389 Adult
17 Cancers. *Cell.* 2018;173(2):355-370 e314.
- 18 48. Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in
19 Pediatric Cancer. *N Engl J Med.* 2015;373(24):2336-2346.
- 20 49. Prot-Bertoye C, Lebbah S, Daudon M, et al. CKD and Its Risk Factors among Patients
21 with Cystinuria. *Clin J Am Soc Nephrol.* 2015;10(5):842-851.
- 22 50. Edvardsson VO, Goldfarb DS, Lieske JC, et al. Hereditary causes of kidney stones and
23 chronic kidney disease. *Pediatr Nephrol.* 2013;28(10):1923-1942.
- 24 51. Milliner DS, Murphy ME. Urolithiasis in pediatric patients. *Mayo Clin Proc.*
25 1993;68(3):241-248.
- 26 52. Sadeghi-Alavijeh O, Chan MMY, Moochhala SH, et al. Rare variants in the
27 sodium-dependent phosphate transporter gene SLC34A3 explain missing heritability
28 of urinary stone disease. *Kidney International.* 2023.
- 29 53. Reed BY, Gitomer WL, Heller HJ, et al. Identification and characterization of a gene
30 with base substitutions associated with the absorptive hypercalciuria phenotype and
31 low spinal bone density. *J Clin Endocrinol Metab.* 2002;87(4):1476-1485.
- 32 54. Mouly C, Vargas-Poussou R, Lienhardt A, et al. Clinical characteristics of familial
33 hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. *Clin*
34 *Endocrinol (Oxf).* 2020;93(3):248-260.
- 35 55. Volpe A, Guerriero A, Marchetta A, Caramaschi P, Furlani L. Familial hypocalciuric
36 hypercalcemia revealed by chondrocalcinosis. *Joint Bone Spine.* 2009;76(6):708-710.
- 37 56. Stratta P, Merlotti G, Musetti C, et al. Calcium-sensing-related gene mutations in
38 hypercalcaemic hypocalciuric patients as differential diagnosis from primary
39 hyperparathyroidism: detection of two novel inactivating mutations in an Italian
40 population. *Nephrol Dial Transplant.* 2014;29(10):1902-1909.
- 41 57. Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR. Primary
42 hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and
43 clinical implications. *Endocr Pract.* 2012;18(3):412-417.
- 44 58. Egan AM, Ryan J, Aziz MA, O'Dwyer TP, Byrne MM. Primary hyperparathyroidism
45 in a patient with familial hypocalciuric hypercalcaemia due to a novel mutation in the
46 calcium-sensing receptor gene. *J Bone Miner Metab.* 2013;31(4):477-480.
- 47 59. Ferraro PM, D'Addessi A, Gambaro G. When to suspect a genetic disorder in a patient
48 with renal stones, and why. *Nephrol Dial Transplant.* 2013;28(4):811-820.

Table 1 | Characteristics of the study cohort. Characteristics are indicated separately for participants with and without kidney stone disease. Categorical variables are described by number of participants N (%), continuous variables are described by their mean (SD) or median (25th-75th percentile). eGFR, estimated glomerular filtration rate; BSA, body surface area; PTH, parathyroid hormone; SD, standard deviation.
* The Non kidney stone formers (NKSF) with LP/P variants (#5948, #5500) have been removed for phenotypic analyses.

Characteristics	Kidney stone formers (N=787)	Non kidney stone formers (N=112) *	p-values
Age, years	46.64 (14.57)	42.41 (14.88)	0.007
Males	565 (71.8%)	61 (54.0%)	<0.001
Body mass index, kg/m ²	26.83 (5.08)	26.34 (4.55)	0.37
Hypertension	255 (36.0%)	28 (35.9%)	1.00
Diabetes	24 (3.1%)	1 (1.1%)	0.50
Obesity, BMI ≥ 30 kg/m ²	168 (22.4%)	14 (15.1%)	0.11
Hyperuricemia	346 (44.0%)	54 (47.8%)	0.48
Family history of kidney stone disease	317 (43.6%)	3 (6.8%)	<0.001
Kidney stone recurrence, > 1 stone event	614 (82.2%)		
Age at first stone event, years	35.41 (13.85)		
Total number of stone events	3.00 (2.00, 4.00)		
Blood parameters			
Total calcium, mmol/L	2.36 (0.12)	2.30 (0.12)	<0.001
Ionized calcium, mmol/L	1.21 (1.19, 1.23)	1.19 (1.18, 1.22)	0.002
Phosphorus, mmol/L	1.01 (0.17)	1.01 (0.16)	0.89
Magnesium, mmol/L	0.83 (0.07)	0.86 (0.08)	<0.001
Uric acid, umol/L	328.96 (169.56)	308.44 (71.51)	0.26
Intact PTH, ng/L	39.06 (30.00, 51.00)	37.50 (30.50, 48.00)	0.56
25-OH Vitamin D ₃ , nmol/L	40.18 (27.00, 59.00)	48.50 (32.72, 72.44)	0.017
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m ² BSA	94.18 (21.08)	96.31 (21.88)	0.36
Urine parameters			
Total urine volume, L/24h	1.98 (1.47, 2.54)	2.10 (1.49, 2.65)	0.41
Urine pH	5.94 (5.39, 6.60)	6.00 (5.50, 6.75)	0.14
Urine sodium / creatinine ratio, mmol/mmol/24h	13.62 (10.97, 16.98)	13.76 (9.92, 16.21)	0.37
Urine potassium / creatinine ratio, mmol/mmol/24h	4.70 (3.77, 5.82)	5.56 (4.43, 6.55)	<0.001
Urine uric acid / creatinine ratio, mmol/mmol/24h	0.61 (0.10)	0.38 (0.27)	<0.001
Urine calcium / creatinine ratio, mmol/mmol/24h	0.43 (0.30, 0.58)	0.33 (0.21, 0.44)	<0.001
Urine magnesium / creatinine ratio, mmol/mmol/24h	0.30 (0.24, 0.38)	0.32 (0.27, 0.42)	0.059
Urine citrate / creatinine ratio, mmol/mmol/24h	0.19 (0.13, 0.27)	0.24 (0.18, 0.30)	0.003
Urine phosphate / creatinine ratio, mmol/mmol/24h	2.18 (0.54)	2.24 (0.57)	0.41
Urine oxalate / creatinine ratio, mmol/mmol/24h	0.03 (0.02, 0.04)	0.03 (0.02, 0.05)	0.062
Stone phenotypes			
Calcium oxalate dihydrate	73 (12.9%)		
Calcium oxalate monohydrate	287 (50.8%)		
Calcium phosphate	130 (23.0%)		
Uric acid	38 (6.7%)		
Cystine	18 (3.2%)		
Struvite	15 (2.7%)		
Bone Mineral Density			
Lumbar Spine BMD, g/cm ²	1.02 (0.14)	1.06 (0.13)	0.011
Lumbar Spine T-Score	-0.57 (1.26)	-0.11 (1.20)	0.005
Lumbar Spine Z-Score	-0.11 (1.38)	0.29 (1.29)	0.024
Femoral neck BMD, g/cm ²	0.84 (0.13)	0.86 (0.12)	0.21
Femoral neck T-Score	-0.55 (1.02)	-0.31 (0.95)	0.076
Femoral neck Z-Score	0.11 (0.99)	0.24 (0.86)	0.30

Table 2: Genotype and phenotype of patients with Mendelian diagnosis. Acc.N°: RefSeq accession number, ACMG: American College of Medical Genetics, AF: allele frequency, AR: autosomal recessive, AD: autosomal dominant, dbSNP: Reference SNP number of variant, het: heterozygous, hom: homozygous, LP: likely pathogenic, P: pathogenic, tot: total, Novel: mutation detected for the first time in this study/not previously described, NS: nonsense, Family history: N=no, Y=yes, M: male, F: female, mo: months, NL: Nephrolithiasis, NC: Nephrocalcinosis, dRTA: distal renal tubular acidosis, PPTH: primary hyperparathyroidism, CKD: chronic kidney disease. Stone analysis: CaOx: Calcium oxalate, COM: Calcium oxalate monohydrate, COD: Calcium oxalate dihydrate, CaP: Calcium phosphate, CA: Carbonate apatite, Brushite: Calcium hydrogen phosphate dihydrate, MAP: Magnesium ammonium phosphate (=Struvite), UA: Uric acid.

ID	Gene	Inheritance	Allelic state	Nucleotide change	Amino acid change	ACMG Class	ACMG criteria	AF gnoMAD (allele/tot/hom) gnoMAD (NFE)	Acc. N° dbSNP	Sex	Age at first stone	Number of past stone events	Stone composition analysis (%)	Family history	Key Phenotype	Clinical diagnosis before WES	Genetic diagnosis after WES
AGXT – Primary Hyperoxaluria Type 1 (PH1)																	
5011	<i>AGXT</i>	AR	hom	c.466G>A	p.Gly156Arg	P	PS1, PM5, PM1, PP2, PM2, PP3, PP5	7/226.862/0 5/101.706/0	NM_000030.3 rs121908530	M	4	8	1) 80 COM, 20 COD 2) 80 COM, 20 COD	N	CaOx NL, normal kidney function Hyperoxaluria (1100)	PH1	PH1
ATP6V1B1 – Distal renal tubular acidosis with sensorineural hearing loss/deafness (AR dRTA)																	
5775	<i>ATP6V1B1</i>	AR	hom	c.242T>C	p.Leu81Pro	P	PP3s, PM2, PP5	1/250.636/0 0/113.172/0	NM_001692.4 rs121964880	M	N/A	>5	100 CA	N	CaP NL, dRTA, medullary NC, sensorineural deafness	AR-dRTA	AR-dRTA
CYP24A1 – (Infantile) HC/NL, 1,25-OH vitamin D-24 hydroxylase deficiency																	
5033	<i>CYP24A1</i>	AR	hom	c.1186C>T	p.Arg396Trp	P	PM2, PM5, PP3m, PP5vs	167/251.228/1 124/113.676/1	NM_000782.5 rs114368325	F	24	1	N/A	Y	NL, osteoporosis, single kidney cyst. Hypercalcemia (total 2.64; ionized 1.4) Normal PTH (47) Normal 25-Vit D (83) Normal 1,25-Vit D (105) Hypercalciuria (7.7)	Idiopathic, infantile HC, NL, s/p parathyroidectomy	(Infantile) HC/NL
5052	<i>CYP24A1</i>	AR	hom	c.1186C>T	p.Arg396Trp	P	PM2, PM5, PP3m, PP5vs	167/251.228/1 124/113.676/1	NM_000782.5 rs114368325	M	N/A	1	N/A	Y	NL, Nephrocalcinosis, multiple kidney cysts, CKD stage 4, Osteopenia, Chondrocalcinosis. Hypercalcemia (total 2.8; ionized 1.41) Low PTH (4) Low 25-Vit D (16) Normal 1,25-Vit D (112) Hypercalciuria (7.2)	Infantile HC/NL, CKD IV° due to NC, s/p parathyroidectomy	(Infantile) HC/NL
5152	<i>CYP24A1</i>	AR	het	c.1186C>T	p.Arg396Trp	P	PM2, PM5, PP3m, PP5vs	167/251.228/1 124/113.676/1	NM_000782.5 rs114368325	M	26	2	N/A	N	NL, multiple kidney cysts. Normocalcemia (total 2.4; ionized 1.26) Low PTH (10) Normal 25-Vit D (87) Normal 1,25-Vit D (177) Hypercalciuria (19)	Idiopathic NL, polycystic kidney disease	(Infantile) HC/NL

ORIGINAL

			het	c.428_430 del	p.Glu143del	P	PM2, BS2, PM4, PP5vs	133/251.266/1 119/113.708/1	rs777676129										
5334	<i>CYP24A1</i>	AR	het	c.1226T>C	p.Leu409Ser	LP	PM2, PP5vs	188/251.066/0 153/113.656/0	NM_000782.5 rs6068812	M	21	3	1) 90 COM, 10 COD; 2) 80 COM, 20 COD	Y	CaOx NL, osteopenia, multiple kidney cysts. Normal plasma calcium (total 2.48; ionized 1.27) Normal plasma magnesium (0.72) Low PTH (9) Normal 25-Vit D (59) Normal 1,25-Vit D (93) Hypercalciuria (14.3)	Idiopathic NL, polycystic kidney disease	(Infantile HC/NL)		
			het	c.400T>G	p.Trp134Gly	LP	PM2, PP3m, PP5s	4/251.146/0 3/113.702/0	rs1170841548										
5794	<i>CYP24A1</i>	AR	hom	c.428_430del	p.Glu143del	P	PM2, BS2, PM4, PP5vs	133/251.266/1 119/113.708/1	NM_000782.5 rs777676129	M	61	2	N/A	N	NL, NC, multiple kidney cysts, incomplete dRTA Normal plasma calcium (total 2.49; ionized 1.25) Low PTH (12) Low 25-Vit D (26) Normal 1,25-Vit D (73) Hypercalciuria (10.2)	Medullary sponge kidney	(Infantile HC/NL)		
GRHPR – Primary hyperoxaluria, type 2 (PH2)																			
5432	<i>GRHPR</i>	AR	hom	c.103del	p.Asp35ThrfsTer11	P	PVS1, PM2, PP5vs	59/248.776/0 57/111.550/0	NM_012203.2 rs80356708	M	28	8	1) 80 COM, 20 COD 2): 90 COM, 10 COD 3): 90 COM, 10 COD	Y	CaOx NL, CKD stage 3 Hyperoxaluria (1796) Low urine glycolate/ high urine glycerate Hypocitraturia (1.3)	PH2, start dialysis at age 57	PH2		
HOGA1 –Primary hyperoxaluria, type 3 (PH3)																			
5595	<i>HOGA1</i>	AR	hom	c.700+5G>T	p.?	P	PM2, PP3m, PP5vs	312/251.412/1 239/113.698/1	NM_138413.4 rs185803104	M	36	5	80 COM, 20 COD	N	CaOx NL, CKD stage 2 Normal urine calcium (2.88) Normal urine oxalate random diet (428-463), high urine oxalate low Ca/Na diet (1090)	Idiopathic NL	PH3		

ORIGINAL UNEDITED

SLC3A1 – Cystinuria type A																	
5030	SLC3A1	AR	het	c.1400T>C	p.Met467Thr	P	PM1, PP2, PM2, PM5, PP3, PP5vs, PP4	627/251.156/4 479/113.498/3	NM_000341.4 rs121912691	F	18	5	80 Cystine, 20 CA	Y	Cystine NL, CKD stage 3, osteoporosis. Urine cystine (115-254 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1617+1G>A	p.?	LP	PVS1s, PM2, PP4	4/250.972/0	rs558461213								
5092	SLC3A1	AR	het	c.851A>G	p.Asp284Gly	LP	PP3s, PM2, PP2, PP4	NF / NF	NM_000341.4 -	M	17	1	100 Cystine	Y	Cystine NL, Urine cystine (263 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1617+5G>A	p.?	LP	PS4m, PM2, PP3m, PP4	NF / NF	-								
5094	SLC3A1	AR	het	c.1400T>C	p.Met467Thr	P	PM1, PP2, PM2, PM5, PP3, PP5vs, PP4	627/251.156/4 479/113.498/3	NM_000341.4 rs121912691	M	54	5	1) 90 CA 10 COM 2) 100 cystine	Y	Cystine NL, CKD stage 2, kidney cysts Urine cystine (247 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.809G>A	p.Arg270Gln	LP	PP3s, PM2, PP2, PP4	2/251.430/0 0/113.720/0	rs142358712								
5156	SLC3A1	AR	hom	c.1400T>C	p.Met467Thr	P	PM1, PP2, PM2, PM5, PP3, PP5vs, PP4	627/251.156/4 479/113.498/3	NM_000341.4 rs121912691	M	22	5	100 cystine	Y	Cystine NL Urine cystine (193-235 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
5162	SLC3A1	AR	het	c.1400T>C	p.Met467Thr	P	PM1, PP2, PM2, PM5, PP3, PP5vs, PP4	627/251.156/4 479/113.498/3	NM_000341.4 rs121912691	F	24	5	100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (267-939 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.787A>C	p.Ser263Arg	LP	PP3m, PM2, PP2, PP4	NF / NF	-								
5168	SLC3A1	AR	het	c.851A>G	p.Asp284Gly	LP	PP3s, PM2, PP2, PP4	NF / NF	NM_000341.4 -	F	18	5	1) 100 cystine 2) 100 cystine 3) 90 cystine, 10 CA	Y	Cystine NL Urine cystine (213-435 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1617+5G>A	p.?	LP	PS4m, PM2, PP3, PP4	NF / NF	-								

5479	<i>SLC3A1</i>	AR	het	c.1400T>C	p.Met467Thr	P	PM1, PP2, PM2, PM5, PP3, PP5vs, PP4	627/251.156/4 479/113.498/3	NM_000341.4 rs121912691	F	22	3	1) 100 cystine 2) 100 cystine	Y	Cystine NL, CKD stage 2 Urine cystine (191-232 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
			het	c.1094G>T	p.Arg365Leu	P	PM1, PP2, PM2, PM5, PP3m, PP5, PP4	2/251.376/0 1/113.678/0	rs567478582								
	<i>SLC7A9</i>	AD/AR	het	C.544G>A	p.Ala182Thr	P	PM2, PM1supp, PP2, PP5vs	727/282810/2 504/113.736/2	NM_014270.5 rs79389353				See above		See above		
5288	<i>SLC3A1</i>	AR	hom	c.647C>T	p.Thr216Met	LP	PP3s, PM2, PP2, PP5, PP4	23/251.414/0 15/113.710/0	NM_000341.4 rs369641941	F	19	5	1)-5) 100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (291-306 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
5578	<i>SLC3A1</i>	AR	hom	c.833T>C	p.Phe278Ser	LP	PP3s, PM2, PP2, PP4	1/251.432/0 1/113.722/0	NM_000341.4 rs762218116	M	20	18	N/A	N	Cystine NL, CKD stage 3 Urine cystine (145-239 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type A
SLC7A9 – Cystinuria, type B																	
5038	<i>SLC7A9</i>	AR	het	c.1316A>G	p.Tyr439Cys	LP	PM2, PP3m, PP2, PP4	NF / NF	NM_014270.5 rs121908483	F	17	28	1) 60 cystine, 40 CA 2) 100 cystine	N	Cystine NL, CKD stage 3 Urine cystine (301 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type B
			het	c.775G>A	p.Gly259Arg	LP	PP3m, PM2, PP2, PP5, PP4	2/251.260/0 2/113.626/0									
5160	<i>SLC7A9</i>	AR	hom	c.313G>A	p.Gly105Arg	P	PM1, PP2, PM5supp, PP3m, PP5, PP4	96/251.028/1 64/113.436/1	NM_014270.5 rs121908480	M	1	4	100 cystine	Y	Cystine NL Urine cystine (286 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type B
5412	<i>SLC7A9</i>	AR	hom	c.313G>A	p.Gly105Arg	P	PM1, PP2, PM5supp, PP3m, PP5, PP4	96/251.028/1 64/113.436/1	NM_014270.5 rs121908480	M	44	5	100 cystine	N	Cystine NL Urine cystine (223 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type B

5716	<i>SLC7A9</i>	AR	hom	c.313G>A	p.Gly105Arg	P	PM1, PP2, PM5supp, PP3m, PP5, PP4	96/251.028/1 64/113.436/1	NM_014270.5 rs121908480	F	16	2	100 cystine	Y	Cystine NL Urine cystine (273 mmol/mol Creatinine) Norm: <30)	Cystinuria	Cystinuria type B
------	---------------	----	-----	----------	-------------	---	-----------------------------------	------------------------------	----------------------------	---	----	---	-------------	---	--	------------	----------------------

SLC12A1 – Bartter syndrome, type 2

5769	<i>SLC12A1</i>	AR	het	c.1493C>T	p.Ala498Val	VUS-LP	PP3s, PM2, PP4	4/152.154/0 0/112.752/0	NM_000338.3 rs1366101480	F	22	1	1) 100 CA 2) 20 COD, 20 Struvite, 60 CA 3) 20 COD, 20 Struvite, 60 CA	N	CaP/CaOx NL, NC, CKD stage 2 Low Plasma K (3.3) High plasma bicarbonate (28) High urine pH (7.0) High PTH (88) Low 25-Vit D (22) Normal 1,25-Vit D (114) Hypercalciuria (5.31) Hypocitraturia (1.8) Normal urine oxalate (219)	Idiopathic NL and NC, CKD, incomplete dRTA	Bartter syndrome type 2
			het	c.1878G>A	p.Trp626Ter	LP	PVS1, PM2, PP4	1/251.116/0 1/113.462/0	rs768765027								

1


2 **Normal/pathologic values laboratory parameters:**

- | | | |
|---|--------------------------------------|-----------------------------------|
| 3 | Plasma calcium (mmol/l): 2.15-2.5 | Hypercalciuria (mmol/24h): >5 |
| 4 | Plasma magnesium (mmol/l): 0.66-1.07 | Hyperoxaluria (µmol/24h): >500 |
| 5 | Plasma phosphate (mmol/l): 0.81-1.45 | Hypocitraturia (mmol/24h): <1.65 |
| 6 | PTH (pg/ml): 15-65 | Urine magnesium (mmol/24h): 3-5 |
| 7 | 25-Vit D (nmol/l): 50-135 | Urine phosphate (mmol/24h): 13-32 |
| 8 | 1,25-Vit D (pmol/l): 48-190 | |

ORIGINAL UNEDITED MANUSCRIPT

Table 3 | Characteristics of stone formers with and without pathogenic gene variants. Characteristics are indicated separately for stone formers with Mendelian disease and with/without LP/P predisposing gene variants. Categorical variables are described by number of participants N (%), continuous variables are described by their mean (SD) or median (25th-75th percentile). eGFR, estimated glomerular filtration rate; BSA, body surface area; PTH, parathyroid hormone; SD, standard deviation.

Characteristics	No genetic diagnosis (N=700)	LP/P variants (N=64)	Mendelian disease (N=23)	p-values
Age, years	47.18 (14.30)	43.73 (15.78)	39.13 (15.83)	0.009
Males	502 (71.7%)	50 (78.1%)	14 (60.9%)	0.27
Body mass index, kg/m ²	26.94 (5.12)	26.56 (4.91)	24.42 (3.15)	0.074
Hypertension	223 (35.4%)	23 (41.1%)	9 (40.9%)	0.57
Diabetes	23 (3.4%)	1 (1.6%)	0 (0.0%)	0.86
Obesity, BMI ≥30 kg/m ²	152 (22.8%)	15 (24.2%)	1 (4.8%)	0.12
Hyperuricemia	306 (43.7%)	28 (43.8%)	12 (52.2%)	0.75
Family history of kidney stone disease	278 (43.1%)	29 (49.2%)	9 (40.9%)	0.66
Kidney stone recurrence, > 1 stone event	547 (82.5%)	49 (79.0%)	18 (81.8%)	0.73
Age at first stone event, years	35.96 (13.76)	33.89 (13.47)	23.48 (12.29)	<0.001
Total number of stone events	3.00 (2.00, 4.00)	3.00 (2.00, 4.00)	5.00 (2.00, 5.00)	0.14
Blood parameters				
Total calcium, mmol/L	2.35 (0.12)	2.38 (0.12)	2.40 (0.11)	0.075
Ionized calcium, mmol/L	1.21 (1.19, 1.23)	1.22 (1.19, 1.25)	1.23 (1.21, 1.25)	0.17
Phosphorus, mmol/L	1.01 (0.17)	0.96 (0.14)	1.07 (0.13)	0.037
Magnesium, mmol/L	0.83 (0.07)	0.84 (0.07)	0.81 (0.07)	0.40
Uric acid, umol/L	328.87 (177.47)	325.73 (74.03)	342.85 (78.56)	0.93
Intact PTH, ng/L	40.00 (30.00, 52.00)	35.60 (27.80, 44.00)	36.00 (22.00, 55.00)	0.069
25-OH Vitamin D ₃ , nmol/L	40.00 (27.00, 59.00)	45.00 (29.50, 60.00)	32.45 (22.00, 73.00)	0.71
eGFR creatinine Equation CKD-EPI 2009, mL/min per 1.73 m ² BSA	96.42 (81.53, 109.15)	99.10 (83.07, 110.36)	93.52 (71.42, 97.96)	0.28
Urine parameters				
Total urine volume, L/24h	1.96 (1.47, 2.50)	2.05 (1.37, 2.59)	2.54 (2.38, 3.30)	<0.001
Urine pH	5.89 (5.35, 6.52)	6.29 (5.60, 6.70)	6.82 (6.63, 7.16)	<0.001
Urine sodium / creatinine ratio, mmol/mmol/24h	13.58 (10.97, 16.79)	12.39 (10.70, 17.20)	18.78 (15.27, 20.41)	<0.001
Urine potassium / creatinine ratio, mmol/mmol/24h	4.69 (3.75, 5.78)	4.26 (3.71, 5.56)	6.52 (5.18, 7.57)	<0.001
Urine uric acid / creatinine ratio, mmol/mmol/24h	0.62 (0.10)	0.59 (0.10)	0.60 (0.14)	0.19
Urine calcium / creatinine ratio, mmol/mmol/24h	0.43 (0.30, 0.58)	0.47 (0.36, 0.60)	0.40 (0.24, 0.53)	0.13
Urine magnesium / creatinine ratio, mmol/mmol/24h	0.30 (0.24, 0.38)	0.28 (0.23, 0.35)	0.38 (0.28, 0.47)	0.039
Urine citrate / creatinine ratio, mmol/mmol/24h	0.19 (0.13, 0.27)	0.20 (0.14, 0.27)	0.22 (0.13, 0.31)	0.72
Urine phosphate / creatinine ratio, mmol/mmol/24h	2.19 (0.55)	2.15 (0.47)	2.15 (0.46)	0.82
Urine oxalate / creatinine ratio, mmol/mmol/24h	0.03 (0.02, 0.04)	0.02 (0.01, 0.04)	0.04 (0.02, 0.05)	0.12
Urine cystine / creatinine ratio, mmol/mol/24h	4.00 (3.00, 5.00)	4.00 (3.00, 6.00)	204.00 (3.00, 263.00)	<0.001
Stone phenotypes				
Calcium oxalate dihydrate	66 (13.1%)	7 (15.9%)	0 (0.0%)	0.24
Calcium oxalate monohydrate	264 (52.4%)	19 (43.2%)	4 (23.5%)	0.035
Calcium phosphate	115 (22.8%)	13 (29.5%)	2 (11.8%)	0.35
Uric acid	37 (7.3%)	1 (2.3%)	0 (0.0%)	0.40
Cystine	7 (1.4%)	0 (0.0%)	11 (64.7%)	<0.001
Struvite	12 (2.4%)	3 (6.8%)	0 (0.0%)	0.17
Bone Mineral Density				
Lumbar Spine BMD, g/cm ²	1.01 (0.14)	1.00 (0.11)	1.11 (0.13)	0.022
Lumbar Spine T-Score	-0.58 (1.28)	-0.71 (1.01)	0.32 (1.05)	0.022
Lumbar Spine Z-Score	-0.11 (1.40)	-0.28 (1.14)	0.64 (1.15)	0.086
Femoral neck BMD, g/cm ²	0.83 (0.13)	0.84 (0.10)	0.89 (0.21)	0.37
Femoral neck T-Score	-0.57 (1.02)	-0.48 (0.87)	-0.14 (1.50)	0.26
Femoral neck Z-Score	0.11 (1.00)	0.09 (0.79)	0.34 (1.39)	0.67



2

3 **Figure 1. Upper Panel: Flowchart of patient inclusion, exclusion and genetic analysis in**4 **the Bern Kidney Stone Registry (BKSR).** Data of 1152 individuals recruited into the BKSR

5 were analyzed. After exclusion of individuals without genetic information available, declined

6 consent or multiple inclusions, the analyzed cohort consisted of 901 individuals (787 stone


1 formers (KSF) and 114 non stone forming controls (NKSF). Before inclusion in the BKSR,
2 NKSF underwent ultrasound imaging to exclude nephrolithiasis (NL) and/or nephrocalcinosis
3 (NC). Genetic analysis was performed in a standardized prioritization pathway in 34 known
4 kidney stone genes. N: number of individuals. Genetic Diagnosis: Likely pathogenic or
5 pathogenic variant according to ACMG criteria. LP/P Variant: monoallelic LP/P variant,
6 predisposing to nephrolithiasis. WES: whole exome sequencing.

7 **Lower Panel: Kidney stone disease gene panel used for genetic analysis.**

8 Panel of 34 known nephrolithiasis genes used with their inheritance mode, as accepted for
9 classification as “Mendelian disease” in this manuscript, grouped by phenotypes. AD:
10 autosomal dominant, AR: autosomal recessive, XLR: X-linked recessive, MODY: maturity-
11 onset diabetes of the young, FRTS: Fanconi renal tubular syndrome.

12

ORIGINAL UNEDITED MANUSCRIPT



2

3 **Figure 2. Overall yield of genetic diagnoses** (A) Diagnostic yield (Mendelian vs. LP/P
 4 variants predisposing to nephrolithiasis) in kidney stone formers (KSF), (B) Diagnostic yield
 5 in non-stone forming controls (NKSF), (C) Overview of Mendelian diagnoses in KSF, sorted
 6 by phenotype groups, (D) Overview of LP/P variants predisposing to nephrolithiasis in KSF,
 7 sorted by phenotype groups.

8

ORIGINAL UNEDITED MANUSCRIPT